Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Pharmaceutical composition for treating rhinitis

A composition and drug technology, which can be used in drug combinations, active ingredients of heterocyclic compounds, antipyretic drugs, etc., can solve problems such as large side effects and lack of non-specific treatment for successful treatment cases.

Inactive Publication Date: 2014-10-22
田华
View PDF2 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0010] For the treatment of allergic rhinitis / conjunctivitis, due to the too many side effects of the introduced agents, the lack of successful treatment cases and non-specific treatment in some cases, the advent of effective and safe combination formulations is extremely awaited

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical composition for treating rhinitis
  • Pharmaceutical composition for treating rhinitis
  • Pharmaceutical composition for treating rhinitis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 2

[0040] Example 2: Preparation of nasal spray or nasal lotion formulation containing citral (1%).

[0041]

[0042] Pour 45kg of pure water into a suitable mixing container with a mixer, and rotate and mix microcrystalline cellulose RC591 at high speed. Then, polysorbate, sorbitol solution, sodium ethylenediaminetetraacetate, and germine were sequentially dissolved and stirred.

[0043] Subsequently, the active ingredient citral is added and mixed with rapid stirring until a homogeneous suspension is produced. The volume was increased to 50 liters with purified water and further mixed. Finally the suspension was evacuated to remove the generated air bubbles. At this point, the resulting suspension is ready to be dispensed into vials.

Embodiment 3

[0044] Example 3: Nasal Spray or Nasal Drops Containing Azelastine Hydrochloride (0.1%, Dissolved) and Citral (1%, Suspended)

[0045]

[0046] Pour 45kg of pure water into a suitable mixing container with a mixer, and rotate and mix microcrystalline cellulose RC591 at high speed. Then, the active ingredient azelastine hydrochloride, the excipient polysorbate, the sorbitol solution, sodium edetate, and germine were successively dissolved and stirred.

[0047] Subsequently, the active ingredient citral is added and mixed with rapid stirring until a homogeneous suspension is produced. The volume was increased to 50 liters with purified water and further mixed. Finally the suspension was evacuated to remove the generated air bubbles.

[0048] At this point, the resulting suspension is ready to be dispensed into vials.

[0049] According to the effect spectrum of some antihistamines and citral, it can be seen that the combined formulation of the two substances has a synergis...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
boiling pointaaaaaaaaaa
boiling pointaaaaaaaaaa
Login to View More

Abstract

The invention discloses a pharmaceutical composition for treating rhinitis. The pharmaceutical composition contains azelastine and citral as active components. The pharmaceutical composition has azelastine content of 0.001-0.5% and citral content of 0.01-5%. According to demands, a pharmaceutically acceptable amount of a carrier and / or a solubiliser and an excipient can be used.

Description

technical field [0001] The present invention relates to a pharmaceutical composition composed of non-sedative antihistamine drugs and leukotriene active substances, wherein the leukotriene active substances can be leukotriene D4 antagonists, 5-lipoxygenase inhibitors or 5-Lipoxygenase-activated protein (FLAP) antagonist. Background technique [0002] Today, allergic diseases are increasing worldwide. Studies have shown that an average of 7.5% of children and adolescents in the world suffer from rhinoconjunctivitis (hay fever and eye syndrome). In Western European countries, the prevalence of the above diseases is particularly significant, about 14%. Recent detailed studies have shown that allergic rhinoconjunctivitis is an inflammatory process in terms of its ongoing inflammatory response. To date, histamine is still considered the most important mediator involved in early inflammation, the most important trigger factor for symptoms including local redness, sneezing, itchi...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/55A61P29/00A61P11/02A61P27/02A61K31/11
Inventor 田华夏先枝
Owner 田华
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com